Principal investigators for the grants are Philip McGlave, M.D., chief of the University of Minnesota Medical School's Hematology, Oncology and Transplant Division and co-leader of the Cancer Center's Translational Research Program, and Jeffrey Miller, M.D., hematologist/oncologist and co-leader of the Transplant Biology and Therapy Program.
"These grants underscore the University of Minnesota's place as a world leader in cell-based experimental therapy. They focus on novel areas of investigation, including the use of umbilical cord blood as a source of stem cells for transplant and the use of natural killer cells to fight cancer," McGlave said.
McGlave will oversee three teams of researchers who will focus on projects aimed at further understanding the biology of human stem cells and transplanting them into patients for treatment of leukemia and lymphoma. In addition to McGlave, University of Minnesota physician-scientists leading the research projects include Stem Cell Institute leaders Catherine Verfaillie, M.D., and John Wagner, M.D. The newly awarded five-year competitive renewal of this grant will enable McGlave and his teams to build on 10 years of National Institutes of Health-funded interdisciplinary programmatic research in this area.
Miller also will direct three teams of researchers who are intent on learning more about the role of natural killer cells in killing cancer and how the cells can be used in unrelated donor transplants. In addition to Miller, the other team leaders include Daniel Weisdorf, M.D., University of Minnesota, and Peter Parham, Ph.D., Stanford University.